RhoA rescues cardiac senescence by regulating Parkin-mediated mitophagy

Area of Science:

• Cardiovascular Biology
• Cellular Mechanisms of Aging
• Mitochondrial Dynamics

Background:

• Heart failure is a major global health concern.
• The role of RhoA, a small GTPase, in cardiomyocyte function and cardiac health remains incompletely understood.
• Understanding RhoA's function is crucial for developing novel therapeutic strategies against heart disease.

Purpose of the Study:

• To investigate the role of cardiomyocyte RhoA in cardiac function and aging.
• To elucidate the molecular mechanisms by which RhoA influences cardiomyocyte health and survival.
• To determine if RhoA-mediated mitophagy is a potential therapeutic target for heart failure.

Main Methods:

• Generation of cardiomyocyte-specific RhoA conditional knockout (cKO) mice.
• Assessment of cardiac structure, function, and lifespan in cKO mice.
• Analysis of mitochondrial morphology, mitophagy, and senescence in cardiomyocytes.
• Investigation of the RhoA-Rho kinase-N-Myc-Parkin signaling axis.
• Validation in human patients with idiopathic dilated cardiomyopathy.

Main Results:

• Cardiomyocyte-specific RhoA deletion resulted in shorter lifespan, cardiac dilation, impaired ejection fraction, fibrosis, and senescence.
• RhoA deficiency inhibited mitophagy and caused mitochondrial structural abnormalities.
• RhoA-Rho kinase signaling downregulates Parkin via N-Myc, impairing mitophagy.
• Parkin re-expression rescued mitophagy, reduced senescence, and improved cardiac function in vitro and in vivo.
• Reduced cardiac RhoA and Parkin expression was observed in patients with idiopathic dilated cardiomyopathy.

Conclusions:

• RhoA is essential for maintaining cardiac function and promoting cardioprotection in aging hearts.
• RhoA facilitates Parkin-mediated mitophagy, crucial for clearing damaged mitochondria and preventing senescence.
• The RhoA-Parkin axis represents a potential therapeutic target for age-related heart failure and dilated cardiomyopathy.